Unknown

Dataset Information

0

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.


ABSTRACT: Lassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact. Caused by Lassa virus (LASV), the disease is a scourge on populations in endemic areas of West Africa, where reported incidence is higher. Here, we report construction, characterization, and preclinical efficacy of a novel recombinant vaccine candidate GEO-LM01. Constructed in the Modified Vaccinia Ankara (MVA) vector, GEO-LM01 expresses the glycoprotein precursor (GPC) and zinc-binding matrix protein (Z) from the prototype Josiah strain lineage IV. When expressed together, GP and Z form Virus-Like Particles (VLPs) in cell culture. Immunogenicity and efficacy of GEO-LM01 was tested in a mouse challenge model. A single intramuscular dose of GEO-LM01 protected 100% of CBA/J mice challenged with a lethal dose of ML29, a Mopeia/Lassa reassortant virus, delivered directly into the brain. In contrast, all control animals died within one week. The vaccine induced low levels of antibodies but Lassa-specific CD4+ and CD8+ T cell responses. This is the first report showing that a single dose of a replication-deficient MVA vector can confer full protection against a lethal challenge with ML29 virus.

SUBMITTER: Salvato MS 

PROVIDER: S-EPMC6789566 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.

Salvato Maria S MS   Domi Arban A   Guzmán-Cardozo Camila C   Medina-Moreno Sandra S   Zapata Juan Carlos JC   Hsu Haoting H   McCurley Nathanael N   Basu Rahul R   Hauser Mary M   Hellerstein Michael M   Guirakhoo Farshad F  

Pathogens (Basel, Switzerland) 20190828 3


Lassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact. Caused by Lassa virus (LASV), the disease is a scourge on populations in endemic areas of West Africa, where reported incidence is higher. Here, we report construction, characterization, and preclinical efficacy of a novel recombinant vaccine candidate GEO-LM01. Constructed in the Modified Vaccinia Ankara (MVA) vector, GEO-LM01 expresses the glycoprotein precursor (GPC) and zinc-bind  ...[more]

Similar Datasets

| S-EPMC5770434 | biostudies-literature
| S-EPMC4154657 | biostudies-literature
| S-EPMC7468113 | biostudies-literature
| S-EPMC9314403 | biostudies-literature
| S-EPMC7925663 | biostudies-literature
| S-EPMC2268497 | biostudies-literature
| S-EPMC5806529 | biostudies-other
| S-EPMC4072895 | biostudies-literature
| S-EPMC2681940 | biostudies-literature
| S-EPMC3260009 | biostudies-literature